TGTX Stock On Track For Best Day In 3.5 Months Amid Fresh Buyout Rumors

The mergers and acquisitions-focused blog Betaville published an alert on Friday signaling fresh interest from an unnamed suitor for TG Therapeutics, Seeking Alpha reported.

• Betaville reportedly categorized it as an “uncooked” alert, defined by it as market gossip that has not been verified through sources.
• Similar rumors emerged in late 2024 about the company garnering interest from big pharma players.
• Earlier this month, TGTX stock fell sharply after it reported earnings per share below Wall Street estimates, though revenue rose drastically.

Shares of TG Therapeutics (TGTX) surged about 10% on Friday, on track to clock its best day since early May, amid fresh buyout speculation.

The mergers and acquisitions-focused blog Betaville published an alert on Friday signaling fresh interest from an unnamed suitor, potentially a mid-to-large U.S. biopharma, for TG Therapeutics, Seeking Alpha reported.

Betaville reportedly categorized it as an “uncooked” alert, defined by it as market gossip that has not been verified through sources, meaning it could also not be true.

This is not the first time that rumors have emerged of buy interest in TGTX. Similar rumors emerged in late 2024 about the company garnering interest from big pharma players including Roche and AstraZeneca.

TGTX Pipeline, Near-Term Catalysts

TG Therapeutics commercializes BRIUMVI for relapsing forms of multiple sclerosis. It is currently administered as two initial intravenous infusions, followed by maintenance infusions.

Full late-stage trial results, evaluating a simplified single 600 mg initiation dose, are due soon, with a supplemental application to the FDA expected later this year and potential 2027 U.S. launch.

The firm is also awaiting topline data from the fully enrolled late-stage subcutaneous BRIUMVI trial supporting quarterly/every-other-month dosing, expected late 2026 or early 2027, which could unlock a self-administered autoinjector option.

TG Therapeutics is also studying BRIUMVI in myasthenia gravis and schizophrenia.

TG’s Q2 Earnings 

Earlier this month, TGTX stock dropped sharply after it reported its second quarter earnings. The company reported earnings per share of $0.05, below Wall Street expectations, though total global revenue hit approximately $240 million—up around 70% year-over-year—driven by U.S. BRIUMVI net sales of about $228 million. Management raised full-year 2026 global revenue guidance to roughly $950 million and U.S. BRIUMVI to $890–$905 million, targeting a ~$1 billion annualized U.S. run rate by year-end.

How Did Retail Traders React?

On Stocktwits, retail sentiment around TGTX rose from bearish to bullish territory over the past 24 hours, while message volume increased from low to high levels.

A Stocktwits user highlighted that the rumors from late 2024 did not materialize and raised doubts about the renewed rumors.

View this Stocktwits post

Another user dismissed the rumors as immaterial and said they are waiting for the stock to reach $120, with or without a buyout deal.

View this Stocktwits post

A third user said that the buyout deal has to value the company at over $20 billion, given its pipeline, which they termed “worth a lot.” The company currently has a market capitalization of about $8.4 billion.

View this Stocktwits post

TGTX stock has gained more than 80% year-to-date. 

For updates and corrections, email newsroom[at]stocktwits[dot]com.<